IPP Bureau
BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies
By IPP Bureau - March 14, 2026
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
By IPP Bureau - March 14, 2026
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
By IPP Bureau - March 14, 2026
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
By IPP Bureau - March 14, 2026
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Almirall opens Shanghai hub to power dermatology innovation and China partnerships
By IPP Bureau - March 14, 2026
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
By IPP Bureau - March 14, 2026
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
GelMEDIX partners with Catalent to advance vision-restoring cell therapies
By IPP Bureau - March 14, 2026
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Veristat expands global trial & regulatory services as Chinese drugmakers push overseas
By IPP Bureau - March 14, 2026
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Biogen unveils promising new data for Salanersen in kids with SMA
By IPP Bureau - March 14, 2026
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Zydus receives USFDA approval for cevimeline hydrochloride capsules
By IPP Bureau - March 14, 2026
Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.
Caplin Steriles gets USFDA approval for potassium phosphates injection
By IPP Bureau - March 14, 2026
Single-use gloves misused across India, raising health risks
By IPP Bureau - March 14, 2026
One task, one interaction, one pair, experts advocate
Aster DM bags overwhelming shareholder backing for merger with Quality Care
By IPP Bureau - March 14, 2026
The endorsement follows overwhelming support for the share swap preceding the merger,
Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing
By IPP Bureau - March 14, 2026
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Wanbury bags key Brazil nod, eyes market expansion
By IPP Bureau - March 14, 2026
Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA
